Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis

Primary endpoint of ocular itch score area under the curve achieved for both tested reproxalap concentrations Key secondary endpoint of clinically relevant two-point ocular itch score improvement achieved for both tested reproxalap concentrations Com... Biopharmaceuticals, Ophthalmology Aldeyra Therapeutics, reproxalap, allergic conjunctivitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news